Wang Chaonan, Cheng Dongyan, Yan Mingming, Wang Lishu
Changchun University of Chinese Medicine, Changchun 130117, China.
Jilin Provincial Academy of Chinese Medicine Sciences, Changchun 130021, China.
Evid Based Complement Alternat Med. 2022 Apr 26;2022:7821724. doi: 10.1155/2022/7821724. eCollection 2022.
The aim of this study was to evaluate the pharmacodynamics of the effective parts from (EPS) . The antihepatic fibrosis and injury effects of EPS were investigated with the following four model animals including the effect on Wistar rats with liver fibrosis induced by complex factors, mice with acute liver injury induced, respectively, by carbon tetrachloride and alcohol, and Sprague-Dawley (SD) rats with acute liver injury caused by D-galactosamine hydrochloride. The pharmacodynamics results showed that the rats' oral administration of EPS can significantly inhibit the formation of liver fibrosis in rats caused by complex factors and has significant preventive and therapeutic effects on acute liver injury caused by various factors as shown by decreased levels of serum biochemical indicators and improved pathological grade. Taken all together, our findings showed that EPS exhibits potent activities and should be considered a good option and an additional source of natural compounds for the treatment of hepatic fibrosis and hepatic injury.
本研究旨在评价[具体药物名称]有效部位（EPS）的药效学。采用以下四种模型动物研究了EPS的抗肝纤维化和肝损伤作用，包括对复合因素诱导肝纤维化的Wistar大鼠、分别由四氯化碳和酒精诱导急性肝损伤的小鼠以及盐酸半乳糖胺诱导急性肝损伤的Sprague-Dawley（SD）大鼠的作用。药效学结果表明，大鼠口服EPS可显著抑制复合因素所致大鼠肝纤维化的形成，对各种因素所致急性肝损伤具有显著的预防和治疗作用，表现为血清生化指标水平降低和病理分级改善。综上所述，我们的研究结果表明，EPS具有强大的活性，应被视为治疗肝纤维化和肝损伤的良好选择及天然化合物的额外来源。
